| HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ... Clinical Cancer Research 23 (17), 5123-5134, 2017 | 55 | 2017 |
| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 30 | 2020 |
| Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer P Upadhyay, S Nair, E Kaur, J Aich, P Dani, V Sethunath, N Gardi, ... Oncotarget 7 (31), 50437, 2016 | 29 | 2016 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 24 | 2019 |
| Drug-sensitiveFGFR3 mutations in lung adenocarcinoma P Chandrani, K Prabhash, R Prasad, V Sethunath, M Ranjan, P Iyer, ... Annals of Oncology 28 (3), 597-603, 2017 | 20 | 2017 |
| Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer V Sethunath, H Hu, C De Angelis, J Veeraraghavan, L Qin, N Wang, ... Molecular Cancer Research 17 (11), 2318-2330, 2019 | 15 | 2019 |
| Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy C De Angelis, C Nagi, CC Hoyt, L Liu, K Roman, C Wang, Y Zheng, ... Clinical Cancer Research 26 (3), 738-745, 2020 | 13 | 2020 |
| GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer RR Bhat, P Yadav, D Sahay, DK Bhargava, CJ Creighton, S Yazdanfard, ... Breast cancer research and treatment 170 (2), 279-292, 2018 | 9 | 2018 |
| Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... Cancer Research 80 (4 Supplement), GS2-01-GS2-01, 2020 | 4 | 2020 |
| High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... CANCER RESEARCH 80 (4), 2020 | 1 | 2020 |
| Pro-oncogenic role of NOTCH1 in early tongue squamous cell carcinoma P Upadhyay, J Aich, V Sethunath, P Dani, S Kannan, P Chandrani, ... Cancer Research 75 (15 Supplement), 4811-4811, 2015 | 1 | 2015 |
| Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast … J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ... Cancer Research 81 (4 Supplement), PD3-09-PD3-09, 2021 | | 2021 |
| Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC) V Sethunath, X Fu, PL Luna, S Nanda, M Shea, J Veeraraghavan, ... Cancer Research 81 (4 Supplement), PS5-29-PS5-29, 2021 | | 2021 |
| Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical Cancer Research, 2021 | | 2021 |
| HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ... Cancer Research 80 (16 Supplement), 1911-1911, 2020 | | 2020 |
| Abstract PD2-02: Activation of the EGFR/RAS/p42, 44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer C De Angelis, ML Cataldo, A Nardone, J Veeraraghavan, X Fu, S Nanda, ... Cancer Research 80 (4 Supplement), PD2-02-PD2-02, 2020 | | 2020 |
| Abstract P3-06-07: ADGRF1 overexpression inhibits tumor growth in vivo by inducing cell cycle arrest in HER2+ breast cancer R Bhat, NM Abdulkareem, L Qin, C De Angelis, H Yasser, H Thangavel, ... Cancer Research 80 (4 Supplement), P3-06-07-P3-06-07, 2020 | | 2020 |
| Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, S Nanda, L Qin, MJ Shea, T Mitchell, ... Cancer Research 80 (4 Supplement), P6-04-02-P6-04-02, 2020 | | 2020 |
| Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, S Nanda, L Qin, MJ Shea, T Mitchell, ... CANCER RESEARCH 80 (4), 2020 | | 2020 |
| Targeting the mevalonate pathway in HER2+ breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy V Sethunath, H Hu, C DeAngelis, J Veeraraghavan, L Qin, M Shea, ... Cancer Research 79 (13 Supplement), 4757-4757, 2019 | | 2019 |
Amit DuttPrincipal Investigator/ Wellcome Trust DBT India Alliance Int Fellow, ACTREC, Tata Memorial CentreVerified email at actrec.gov.in
